A federal appeals court ruled on August 27, 2026, against a lawsuit filed by representatives of the pharmaceutical industry that challenged the federal Medicare drug price negotiation program. The U.S. Court of Appeals for the 5th Circuit found that drugmakers do not have the right to sell their products to Medicare at a price of their choosing. This ruling affirms a prior decision regarding the program.
✓ AI-Debiased Article
4
Wire-neutral
provisional
✓ No loaded language, vague sourcing, or framing detected.
Federal appeals court upholds Medicare drug price negotiation program
On August 27, 2026, the U.S. Court of Appeals for the 5th Circuit ruled against a lawsuit from the pharmaceutical industry challenging the Medicare drug price negotiation program. The court determined that drugmakers are not entitled to set their own prices for products sold to Medicare.
Annotating as
No note attached
on this article.
Original vs. Neutral
Original Headline
Federal court rejects PhRMA challenge to Medicare drug price negotiation
Neutral Headline
Federal appeals court upholds Medicare drug price negotiation program